Articles published by FORE Biotherapeutics

FORE Biotherapeutics to Present New Clinical and Preclinical Plixorafenib Data at Upcoming Oncology Medical Meetings

November 04, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

September 01, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions

September 01, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements

July 07, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

May 12, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib

April 01, 2026

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

November 04, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Host Virtual Key Opinion Leader Roundtable Discussion on Plixorafenib’s Potential to Disrupt the BRAF Market to Benefit Patients

October 13, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

September 24, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting

September 12, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

August 27, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib

May 22, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting

April 30, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients

April 25, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium

February 13, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Highlights Recent Pipeline Achievements for its Targeted-Oncology Program and Provides Strategic Objectives for 2025

January 09, 2025

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 19, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in the Wells Fargo Virtual Private Biotech Symposium

December 05, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming November Conferences

November 07, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

September 04, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer

August 12, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present Nonclinical Data at the 2024 AACR Annual Meeting Supporting Superior Potency for Plixorafenib Compared with BRAF or Pan-Raf Inhibitors, When Combined with MEK Inhibition

April 09, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer

February 29, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

February 01, 2024

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

December 07, 2023

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors

November 17, 2023

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting

November 10, 2023

From FORE Biotherapeutics

Via Business Wire

FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference

October 12, 2023

From FORE Biotherapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.